Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Gamida Cell Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 0/6

Gamida Cell şirketinin toplam hissedar öz sermayesi $-18.7M ve toplam borcu $75.1M olup, bu da borç-öz sermaye oranını -401% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $79.6M ve $98.3M dir.

Anahtar bilgiler

-401.0%

Borç/özkaynak oranı

US$75.10m

Borç

Faiz karşılama oranı	n/a
Nakit	US$24.78m
Eşitlik	-US$18.73m
Toplam yükümlülükler	US$98.29m
Toplam varlıklar	US$79.56m

Son finansal sağlık güncellemeleri

Does Gamida Cell (NASDAQ:GMDA) Have A Healthy Balance Sheet?

Feb 23

Gamida Cell (NASDAQ:GMDA) Has Debt But No Earnings; Should You Worry?

Nov 02

Recent updates

Gamida stock rises 13% as FDA grants priority review to stem cell therapy omidubicel

Aug 01

Does Gamida Cell (NASDAQ:GMDA) Have A Healthy Balance Sheet?

Feb 23

Gamida Cell: Recapping A Tough Year

Nov 02

Gamida Cell (NASDAQ:GMDA) Has Debt But No Earnings; Should You Worry?

Nov 02

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: GMDA.Q negatif hissedar özkaynağı var; bu, kısa vadeli varlıkların kısa vadeli yükümlülükleri karşılamamasından daha ciddi bir durumdur.

Uzun Vadeli Yükümlülükler: GMDA.Q şirketinin negatif özkaynağı bulunmaktadır; bu, kısa vadeli varlıkların uzun vadeli yükümlülükleri karşılamamasından daha ciddi bir durumdur.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: GMDA.Q negatif hissedar özkaynağı var ki bu yüksek borç seviyesinden daha ciddi bir durumdur.

Borcun Azaltılması: GMDA.Q 'in negatif özkaynağı var, dolayısıyla borcunun zaman içinde azalıp azalmadığını kontrol etmemize gerek yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: GMDA.Q şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: GMDA.Q un, serbest nakit akışı her yıl % 20.2 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

Gamida Cell Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 0/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Gamida Cell Files Form 15

Gamida Cell Ltd. announced delayed 10-Q filing

Gamida Cell Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement of Nasdaq Listing Rule 5450(a)(1)

Gamida Cell Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement of Nasdaq Listing Rule 5450(a)(1)

Does Gamida Cell (NASDAQ:GMDA) Have A Healthy Balance Sheet?

Gamida Cell (NASDAQ:GMDA) Has Debt But No Earnings; Should You Worry?

Recent updates

Gamida Cell Ltd. announced that it has received $30 million in funding from Highbridge Capital Management, LLC

Gamida Cell Ltd. Names Joe Wiley as Chief Executive Officer

Gamida Cell Files Form 15

Gamida Cell Ltd. announced delayed 10-Q filing

New major risk - Negative shareholders equity

Gamida Cell Ltd. announced that it expects to receive $30 million in funding from Highbridge Capital Management, LLC

Gamida Cell Ltd. to Report Q4, 2023 Results on Mar 27, 2024

Gamida Cell Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement of Nasdaq Listing Rule 5450(a)(1)

Gamida Cell Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement of Nasdaq Listing Rule 5450(a)(1)

Gamida Cell Ltd. Announces Resignation of Mr. Jeremy Blank as Board of Director

Price target decreased by 43% to US$4.00

Gamida Cell Ltd. has filed a Follow-on Equity Offering in the amount of $50 million.

Gamida Cell Presents New Data on Allogeneic Stem Cell Therapy Omidubicel and Natural Killer (NK) Cell Therapy Candidate GDA-201 at Society for Immunotherapy of Cancer Annual Meeting

Gamida Cell Ltd. to Report Q3, 2023 Results on Nov 14, 2023

New minor risk - Market cap size

Gamida Cell Ltd. Reports Preliminary Data from Phase 1 Study of Natural Killer Cell Therapy Candidate GDA-201

New minor risk - Share price stability

Gamida Cell Ltd. Announces First Patient Receives Omisirge (Omidubicel-Onlv)

Gamida Cell Ltd., Annual General Meeting, Oct 19, 2023

Consensus EPS estimates fall by 12%

Gamida Cell Ltd. to Report Q2, 2023 Results on Aug 14, 2023

Gamida Cell Ltd. Announces Publication in Prospective Sub- Study of the Phase 3 Clinical Trial for Omisirge®

Forecast to breakeven in 2025

Gamida Cell Ltd. Appoints Terry Coelho as its Principal Financial Officer and Principal Accounting Officer

Price target decreased by 11% to US$6.80

Gamida Cell Ltd. to Report Q1, 2023 Results on May 15, 2023

Forecast to breakeven in 2025

Consensus revenue estimates increase by 70%

Forecast to breakeven in 2025

Price target decreased by 48% to US$6.40

Data Presented on Gamida Cell’s Omidubicel, GDA-201 at the 2023 Tandem Meetings of ASTCT and CIBMTR

Gamida Cell Ltd. announced that it has received $25 million in funding from Highbridge Capital Management, LLC

Gamida Cell Ltd. Provides Regulatory Update on Omidubicel

Price target decreased to US$12.60

Gamida Cell Ltd. Announces Encouraging Preclinical Data on GDA-501

Independent Chairman of the Board recently bought US$78k worth of stock

Gamida Cell Ltd. announced that it expects to receive $25 million in funding from Highbridge Capital Management, LLC

Gamida Cell shares slide after stock offering

Gamida Cell Ltd. Announces Executive Changes

Gamida appoints Emergent’s former head of vaccines as new CEO

Gamida Cell Q2 2022 Earnings Preview

Gamida Cell Announces Dosing of First Patient in Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201

Gamida Cell Announces FDA Acceptance of Biologics License Application for Omidubicel with Priority Review

Gamida stock rises 13% as FDA grants priority review to stem cell therapy omidubicel

Gamida Cell Ltd., Annual General Meeting, Jul 27, 2022

No longer forecast to breakeven

Gamida Cell Ltd. Announces Board Changes

Gamida Cell Completes Rolling Biologics License Application Submission to the FDA for Omidubicel

Gamida Cell Announces Opening to Enrollment of Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201

Gamida Cell Presents New Data from NAM-Enabled Genetically Modified Natural Killer (NK) Pipeline at International Society for Cell & Gene Therapy 2022

Gamida Cell Ltd. Presents Updated One-Year Post-Transplant Follow Up Data from Phase 3 Study of Omidubicel At 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings

Price target decreased to US$15.00

Gamida Cell Announces FDA Clearance of IND and Removal of Clinical Hold for NK Cell Therapy Candidate GDA-201

Gamida Cell Ltd. Presents Updated Omidubicel Data During Best Abstract Award Session at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings

Consensus forecasts updated

Does Gamida Cell (NASDAQ:GMDA) Have A Healthy Balance Sheet?

Gamida Cell Initiates Rolling Submission of Biologics License Application for Omidubicel

Forecast to breakeven in 2024

Gamida Cell Ltd. Announces Board Appointments

Gamida Cell Provides Update on Omidubicel BLA Submission

Gamida Cell Presents New Omidubicel Data at 63rd ASH Annual Meeting

Independent Director David Fox has left the company

Price target decreased to US$14.57

Price target decreased to US$17.86

Gamida Cell: Recapping A Tough Year

Gamida Cell (NASDAQ:GMDA) Has Debt But No Earnings; Should You Worry?

Independent Director Nurit Benjamini has left the company

Gamida Cell Announces Publication in Blood, the Journal of the American Society of Hematology, of the First Pivotal Trial to Evaluate a Cell Therapy (Omidubicel) for Patients with Blood Cancer who Require an Allogeneic Stem Cell Transplant

Finansal Durum Analizi